FY21 Results 7th December 2021

Giulio Cerroni

Grant Nash

CEO

CFO

Nonregulated Disclaimer

This presentation is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which includes certain information drawn from public sources does not purport to be comprehensive and has not been independently verified. It has been prepared and issued by and is the sole responsibility of the Company.

No reliance may be placed for any purpose whatsoever on the information contained in this presentation or any assumptions made as to its completeness. No representation or warranty, express or implied, is given by the Company, any of its subsidiaries or any of its advisors, directors, officers, employees or agents, as to the accuracy, reliability or completeness of the information or opinions contained in this presentation or in any revision of the presentation or of any other written or oral information made or to be made available to any information or opinions (which should not be relied upon) and no responsibility is accepted for any errors, misstatements in or omissions from this presentation or for any loss howsoever arising, directly or indirectly, from any use of this presentation or its contents. The information and opinions contained in this presentation are provided as at the date of this presentation and are subject to change without notice.

In particular, this presentation may contain certain forward-looking statements that are subject to the usual risk factors. Whilst the Company believes the expectations reflected herein to be reasonable in light of the information available to them at this time, the actual outcome may be materially different owing to factors beyond the Company's control or with in the Company's control where, for example the Company decides on a change of strategy. Accordingly no reliance may be placed on the figures or other indications contained in any such potential forward-looking statements. No representation or warranty of any kind is made with respect to the accuracy or completeness of the financial projections or other forward-looking statements, any assumptions underlying them, the future operations or the amount of any future income or loss.

The content of this presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). This presentation does not constitute or form part of any offer or invitation to see, or any solicitation of any offer to purchase or subscribe for or otherwise acquire, any securities in the Company in any jurisdiction or any other body corporation or an invitation or an inducement to engage in investment activity under section 21 of FSMA, nor shall it or any part of it form the basis of or be relied on in connection with any contract therefore. This presentation does not constitute an invitation to effect any transaction with the Company or to make use of any services provided by the Company. Reliance on the information contained in this presentation for the purposes of engaging in any investment activity may expose the investor to a significant risk of losing all of the property or assets invested. Any person who is in any doubt about the investment in business to which this presentation relates should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.

By attending the presentation or reading or accepting this document you agree to be bound by the foregoing limitations.

IXICO plc is incorporated in England with registered number 3131723 and registered address 15 Long Lane, London, EC1A 9PN.

2

Delivering on our Purpose

3

IXICO: A company invested in a meaningful purpose

To advance medicine and human health by turning medical imaging data (brain scans) into clinically meaningful information.

We enable our pharmaceutical clients to gain valuable new insights to

accelerate the development of new medicine in neuroscience.

  1. 55m people with dementia globally o Forecast to grow to 78m by 2030 o 10m new cases every year*
  1. $1.3tr global cost of dementia
  1. Forecast to grow to $2.8tr by 2030
  1. Funding by NIH > doubled in 4 years**

The GAP BioHermes study aims to reduce the cost and challenges of identifying patients to participate in AD clinical trials. IXICO is contracted as the Imaging

C-Path is a public-private partnership with the FDA aimed at increasing the efficiency of developing new treatments. IXICO is a member of the C-PathAD, HD and PD

ADNI is public-private longitudinal study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of AD. IXICO is a

DPUK brings together scientific minds and global leaders in the pharmaceutical industry to find new ways of detecting, treating and preventing dementia. IXICO is a

FARA is dedicated to the pursuit of scientific research leading to treatments and a cure for Friederichs's ataxia. IXICO is contracted as an Imaging partner

partner for the BioHermes study initiatives.

member of ADNI

chosen Imaging Company Partner to DPUK

to FARA

*https://www.who.int/news-room/fact-sheets/detail/dementiaSep-21

4 **https://alzimpact.org/issues/research

Impact of Aduhelm: First disease modifying drug for AD

Jun-21 FDA approved Aduhelm for clinical

use in AD

  • Expensive
  • Clinical benefit uncertain
  • Known side effects
  • Requirement for further studies & post-market surveillance
  • Increased investment in neuro drug devt.
  • Increased focus on objective detailed measures (patient selection, patient safety, new biomarkers).

5

2021 FDA breakthrough therapy designations

in AD

  • 3 'breakthrough therapy' designations issued by
    FDA;
  • Biogen precedent suggests small improvements in patient prognosis warrant drug approval
  • Ability to objectively measure clinically meaningful changes in the brain critical to health and commercial outcomes

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

IXICO plc published this content on 07 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 December 2021 13:38:02 UTC.